In Novo Nordisk’s full-year financial report, which was released on Wednesday morning, the Danish pharmaceutical giant predicts less growth in 2022 than what it just booked in 2021. The company also estimates that its 2022 sales growth will land in the 6–10 percent range in constant exchange rates (CER) compared to 14 percent in 2021, while the operating profit growth will be between 4–8 percent at CER against the reported 13 percent in 2021.
Prior to the report, analysts had predicted top line growth of 7.8 percent at CER and operating growth of 5.4 percent.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Novo Nordisk invests additional millions of dollars in new manufacturing facilities
Novo Nordisk’s DKK 17bn (USD 2.4bn) investment into upgrading and building new facilities in Kalundborg last year has now been followed by a DKK 1bn (USD 143.8m) investment in the same location.
CHMP to remove 100 generic medicines from market
Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.
Germany orders 40,000 monkeypox vaccines from Bavarian Nordic
The German Minister for Health has revealed that the German state has ordered vaccines from Bavarian Nordic, as the country reports 5 cases of monkeypox.
New head of research at Astellas Gene Therapies: "Choosing the right indications is extra important"
Morten Søgaard is leaving Pfizer to join Astellas, where he will be in charge of 100 employees. Going from one of the world largest pharmaceutical firms to a considerably smaller one will be a challenge, he says.
Rumored purchase of GN Group could mean divestment of hearing aid division, says media
Inside Business has learned that a number of buyers might be looking to buy GN Store Nord stock while it’s cheap, with the plan to sell one division, GN Hearing, while keeping Audio.
IRT Manager, Clinical Drug Supply 
CMO Operations Specialist - screening & selection of CMO/CDMO’s 
System Sales Development Consultant - Investment Projects, Merck Millipore 
Director for innovative pre-clinical testing unit 
Nordic Medical Affairs Manager 
2 Sales Representatives and Product Specialists 
Senior IT Network Engineer 
Senior Chemical Safety Advisor 
Analytical Senior Scientist 
Quality System Manager 
KLIFO is looking for a Clinical Supply Manager for our Glostrup office 
Senior Project Manager (GMP - Life Science) 
Clinical Trial Manager 
(Senior) Drug Substance Specialist 
Industrial Designer- Design Engineer 
Production Director 
Project Manager & Scrum Master 
Director Global Engineering